IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Holtzman, Douglas A. in re application of:

09/782,980 Application No.:

February 13, 2001

Filed: For:

1652 Group No.:

NOVEL ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, AND STMST PROTEIN Maryam Monshipouri, Ph.D.

AND NUCLEIC ACID MOLECULES AND USES THEREFOR

Commissioner for Patents.

Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Madam:

REMARKS

the non-elected subject matter in other applications in the event a generic claim is not found allowable. host cells, kits comprising said sequences, and methods of expressing said sequences (claims 1-7, 12, 18, and 53-54), with traverse. This election is made without prejudice to Applicant's right to pursue hereby elect Group 9b, drawn to isolated DNA sequences encoding human STMST-2 polypeptides, In response to the Restriction Requirement dated June 12, 2003 (Paper No. 11), Applicants

Applicants respectfully traverse the present restriction and reserve the right to petition therefrom under 37 C.F.R. § 1.144 and for the reasons set forth below.

CERTIFICATION UNDER 37 C.P.R. SECTIONS 1.8(a) and 1.10

I hereby certify that, on the date shown below, this correspondence is being:

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. MAILING

as "Express Mail Post Office to Address" Mailing Label No.

37 C.F.R. SECTION 1.10*

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

with sufficient postage as first class mail.

 $oldsymbol{\Sigma}$

37 C.F.R. SECTION 1.8(a)

D

Mary MacKinnon

July 14, 2003

Date:

Signature '

(type or print name of person certifying)

Elected as Separate Species of a Common Genus

As seen in the enclosed protein sequence alignment (Exhibit A), the sequences of SEQ ID NOs:71 and which is a 609 residue protein, comprises the majority portion of SEQ ID NO:71 (STMST-1), which is encoding STMST-1 and a truncated version of the open reading frame encoding STMST-2 (Exhibit B, a 297 residue protein. Both protein sequences share the first 262 residues, which constitute over 88% STMST-1 and STMST-2, respectively) should be examined together, as species of a common genus. Applicants submit that the separate nucleic acid sequences encoding SEQ ID NOs:71 and 74 sequences are even more similar, as evidenced by the enclosed alignment of the open reading frame 74 (and the nucleic acid sequences encoding them) are related in that SEQ ID NO:74 (STMST-2) of the entire length of the STMST-1 protein. The nucleic acid sequence encoding the protein showing 93% sequence identity over the length of the STMST-1 open reading frame)

SEQ ID NO:74 includes by necessity a search and examination of the nucleic acids that encode SEQ virtually the same search and examination, since searching and examining nucleic acids that encode The inclusion of both nucleic acids which encode SEQ ID NOs:71 and 74 in the current election does not pose a serious examination burden on the Examiner. In fact, it would require D NO:71 (SEQ ID NO:71 shares residues 1-262 of SEQ ID NO:74). This paper is being filed timely, as it is believed that no extensions of time are required. In the event any extensions of time are deemed necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

MILLENNIUM PHARMACEUTICALS, INC. Paul J. Pagligani

Registration No. 52,498 75 Sidney Street

Cambridge, MA 02139

Telephone - 617-761-6865

Facsimile - 617-551-8820

609 aa BLOSUM50, gap penalties: -12/-2 Global alignment score: 1198	10 20 30 40 50 60 MSDERRLPGSAVGWLVCGGLSLLANAWGILSVGAKQKKWKPLEFLLCTLAATHMLNVAVP :::::::::::::::::::::::::::::::::::	70 80 90 100 110 120 IATYSVVQLRRQRPDFEWNEGLCKVFVSTFYTLTLATCFSVTSLSYHRWMVCWPVNYRL ::::::::::::::::::::::::::::::::::::	130 140 150 160 170 180 SNAKKQAVHTVMGIWMVSFILSALPAVGWHDTSERFYTHGCRFIVAEIGLGFGVCFLLLV ::::::::::::::::::::::::::::::::::	190 200 210 240 GGSVAMGVICTAIALFQTLAVQVGRQADHRAFTVPTIVVEDAQGKRRSSIDGSEPAKTSL ::::::::::::::::::::::::::::::::::::	250 260 QTTGLVTTIVFIYDCLMGFPVLD-STPIP ::::::::::::::::::::::::	270 BRS	REKCMALMANDEESDDETSLEGGISPDLV 320 330 34	280AVRQG	3dOQX	LAALAHLVLPAGPERRRASLLAFAEDAPPSRARRRSAESLLSLRTSALDSGPRGARDSPF 430 440 450 460 470 480	*	: GSPRRRPGPGPRSASASLLPDAFALTAFECEPQALRRPPGPFPAAPAAPDGADPGEAPTP 510 520 530 540	
matrix: Wentity;	10 MSDERRLPGSAVGWI ::::::::::::: MSDERRLPGSAVGWI 10	70 IATYSVVQLRRQRPI :::::::::::: IATYSVVQLRRQRPI 70	130 SNAKKQAVHTVMGIV ::::::::::::::::::::::::::::::::::::	190 GGSVAMGVICTALAI :::::::::::: GGSVAMGVICTALAI	250 260 Z60 Z60 ZFO ZFOLMGFPVL		DRYRADLKAVREKCI 310	AVRQG :::: YEISALEGGLPQLY		LAALAHLVLPAGPE 430	g9	: GSPRRPGPGPRSA 490	290 PSSRO
>STMST1 >STMST2 scoring 46.8% ic	STMST2	STMST1 STMST2	STMST1 STMST2	STMST1 STMST2	STMST1 STMST2	CHONE CHILL	STMST2	STMST1 STMST2	STMST1	STMST2	STMST1	STMST2	CTTM CTT-1

STMST1 --DCL---P : : STMST2 HSDSLGSAS

	60 3GGGGCCTC 5:::::::::	120 \AGTGGAAG ::::::: \AGTGGAAG	180 sccerccc :::::::: sccerccc	240 IGGAATGAG :::::::: IGGAATGAG 240	300 TGTTTCTCT :::::::: TGTTTCTCT	360 TACCGGCTG :::::::: TACCGGCTG 360	420 TCCTTCATC :::::::: TCCTTCATC	480 ACCCATGGC :::::::: ACCCATGGC	540 CTGCTGGTG :::::::: CTGCTGGTG	600 ACGCTGGCC
891 nt	50 GCTGGTATGTG ::::::::: GCTGGTATGTG	110 CAAGCAGAAGA :::::::::: CAAGCAGAAGA	170 GCTAAATGTGG ::::::::::::::::::::::::::::::	230 :CGACTTCGAG7 :::::::::::::::::::::::::::::::::::	290 :ccTGGCCACC' :::::::::::::::::::::::::::::::::	350 scctgtcaac; ::::::::::	410 FCTGGATGGTG ::::::::: FCTGGATGGTG	470 AGCGCTTCTAC :::::::: AGCGCTTCTAC	530 rcrectyccre ::::::::: rcrectyccre	590 CCCTCTTCCAG
-4 score:	10 20 30 40 50 60 ATGAGTGATGAGCGGCGGCTGCCAGTGGCTGGCTGGTATGTGGGGGCCTC :::::::::::::::::::::::::::	70 80 100 110 120 TCCCTGCTGGCCATCCTCAGCGTTGGCGCCAAGCAGAAGAAGAAG ::::::::::::::::::	130 140 150 160 170 180 CCCTTGGAGTTCCTGCTGTTACGCTCGCGGCCACACACATGCTAAATGTGGCCGTGCCC ::::::::::::::::::::::::::	190 200 210 220 230 240 ATCGCCACCTACTCCGTGCTGCGGCGGCGCCGCCCCGACTTCGAGTGGAATGAG :::::::::::::::::::::::::::	250 260 300 380 290 300 6GTCTCTGCAAGGTCTTCGTGCCACCTGGCCACCTGTTTCTCT ::::::::::::::::::::::::::::	310 320 340 350 360 360 350 360 360 350 360 360 350 360 360 360 360 360 360 360 360 360 36	370 380 390 400 410 420 AGCAATGCCAAGAAGCAGGGGTGCACACAGTCATGGGTATCTGGATGGTGTCCTTCATC ::::::::::::::::::::::::::::::	430 440 450 460 470 480 CTGTCGGCCCTGCCTTGGCTTGGCACGCACACGCAGCGCTTCTACACCCATGGC :::::::::::::::::::::::::::::::::::	490 500 510 520 530 540 TGCCGCTTCATCGTGGCTGAGATCGGCCTTTGGCGTCTGCTTCCTGCTGGTG ::::::::::	550 560 500 600 500 580 590 600 500 590 600 500 500 500 500 500 500 500 500 50
penalties: -16/. Global alignment	30 GCCTGGCAGTC :::::::::: GCCTGGCAGTC 30	90 GGGCATCCTC2 :::::::::::: GGGCATCCTC3	150 TACGCTCGCGC ::::::::::: TACGCTCGCGC	210 GCAGCTGCGG ::::::::::::::::::::::::::::::::	GTCCACCTTCT GTCCACCTTCT GTCCACCTTCTCT	330 CCGCATGTGG :::::::::: CCCGCATGTGG	390 CGGTGCACACACACACACACACACACACACACACACACAC	450 FTGGCTGGCAC(:::::::::: FTGGCTGGCAC(510 AGATCGGCCTG ::::::::: AGATCGGCCTG) SCGTGATCTGC
A, gap	20 GCGGCGGCT ::::::::: GCGGCGCT	80 CAATGCCTG :::::::::::::::::::::::::::::::::	140 CCTGCTGTG :::::::::::::::::::::::::::::	200 ACTCCGTGGT :::::::: ACTCCGTGGT	260 AGGTCTTCGT(:::::::: AGGTCTTCGT(320 CCTCCTACCA ::::::::::::::::::::::::::::	380 AGAAGCAGGC(::::::::: AGAAGCAGGC(380	440 recerecer ::::::: recerecer	500 rcgrggcrga ::::::::: rcgrggcrga	56) TGGCCATGG
(truncated) matrix: DNA, dentity;	10 ATGAGTGATGA ::::::::: ATGAGTGATGA 10	70 ICCCTGCTGGC ICCCTGCTGGC	130 CCCTTGGAGTI ::::::::: CCCTTGGAGTI	190 ATCGCCACCTA :::::::::: ATCGCCACCTA	250 GGTCTCTGCAA :::::::::: GGTCTCTGCAA 250	310 GTCACCTCCCT ::::::::::: GTCACCTCCCT	370 AGCAATGCCAAAAGCAAAAAAAAAAAAAAAAAAAAAAAA	430 crerceecer: :::::::: crerceecec	490 TGCCGCTTCA	550 GGCGGGG
>stmst1 >stmst2 scoring 93.0% id	/tmp/s / : Btmst2 /	/tmp/s]	/tmp/s (stmst2 (/tmp/s /	/tmp/s (stmst2 (/tmp/s	/tmp/s stmst2	/tmp/s stmst2	/tmp/s stmst2	#/ cm+/

660 TGGTGGAG ::::::: TGGTGGAG	720 CCTCTCTG ::::::: CCTCTCTG	780 GCTTCCCT :::::: GCTTCCCT 780	GACTGG :::: CCCTGGAT 830	890 ?rgccrrcc-c :::::::: ?rgrgrrccrc
650 ::::::::::::::::::::::::::::::::::::	710 CCGCCAAAA CCGCCAAAA	770 recercares ::::::::::	830 SAGGG-AGAGG : : : SGCCTCAGCGC 820	880 CAAGACTGCC : :: SCTGCCTGTG
640 TTCACCGTGC ::::::::: TTCACCGTGC 640	700 GGCTCGGAGG :::::::::: GGCTCGGAGG	760 ::::::::::::::::::::::::::::::::::::	10 820 830 GGTCTGCAGTGAGACAGGG-AGAGGACTGG :::: :::: ::::CTGCGGCCGACGCCTCAGCCCTGGAT 810 820 830	870 AGCAGCAGG :: AGGCCCTGCTV 870
630 CCACCGCGCC CCACCGCGCC 630	690 CTCCATCGAT CTCCATCGAT 690	750 CATAGTCTTC ::::::::: CATAGTCTTC	810 CGAAAGGTCT : :: CCT	TCATCCA : : : : : : : : : : 860
620 ccaggccaac ::::::::: ccaggccgac 620	089 CEGECECTO CEGECETO CEGEC CEGEC CEGEC CEGEC CEGEC CEGEC CEGEC CEGEC CEGEC CEGEC CEGE CEGEC CEGE CEG CEG	740 CGTGACCAC(::::::::: CGTGACCAC(740	800 GCCCATCCC ::: CTTCAGCAG	860 TGAGGGGTT :::::: TTGTGGTGCTG
610 620 630 640 650 660 /tmp/s GrGCAGGTGGGCCCAGGCCGACCACGCGCCTTCACGGTGCCCACCATCGTGGTGGAG ::::::::::::::::::::::::::::::	670 680 710 720 GACGCGCAGGCCAAGCGCCCTCCATCGATGGCTCGGAGCCCGCAAAACCTCTG :::::::::::::::::::::::::::::::::	/tmp/s CAGACCACGGGCCTCGTGACCACCATCTTCATCTACGACTGCCTCATGGGCTTCCCT::::::::::	790 800 810 820 830 GTGCTGGACTCTACGCCCATCCCCGAAAGGTCTGCAGTGAGACAGGG-AGAGGACTGG- :::::::::::::::::::::::::::::::::::	840 850 860 870 880 890
/tmp/s G : stmst2 G	/tmp/s G : stmst2 G	/tmp/s C : stmst2 C	/tmp/s G : stmst2 G	/tmp/s G stmst2 G

Practitioner's Docket No. MP100-544OMNIM	PATENT
Certificate of Transmission under 37 CFR 1.8	FAX FECE VED ar 37 CFR 1.8 JU 15 ART
I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office	ලෙබ්රීම් ලෙක්ත්රියම් ලෙක්ත්රියම්
On July 14, 2003. Many MacKinnon Typed or printed name of person signing Certificate	g Certificate
Note: Each paper must have its own certificate of transmission, or this certificate must Identify each submitted paper.	certificate must Identify
Submitted herewith: Response to Restriction Requirement Exhibit A Exhibit B Total	(2 pages) (2 pages) (2 pages) (7 pages-including fax cover sheet)
TO/SB/97 (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Petent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.	action of information unless it contains a valid OMB control

Office, Washington, DC 20231. DO NOT SEND FEES UK CUMPLE LEU FURMS 10 11110 ALCOHOL